Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024
Zevra Therapeutics (ZVRA) announced its upcoming addition to the Nasdaq Biotechnology Index (NBI) effective December 23, 2024, as part of the annual index reconstitution. The inclusion reflects the company's meeting of eligibility requirements, including minimum market capitalization, average daily trading volume, and biotechnology industry classification.
The NBI tracks the performance of biotechnology and pharmaceutical securities listed on Nasdaq under a modified capitalization-weighted methodology. CEO Neil F. McFarlane highlighted this as a transformational year for Zevra, noting that the index inclusion will raise the company's profile among biotech funds and portfolio managers.
Zevra Therapeutics (ZVRA) ha annunciato la sua prossima inclusione nell'Indice Biotecnologico Nasdaq (NBI), a partire dal 23 dicembre 2024, come parte della ristrutturazione annuale dell'indice. L'inclusione riflette il soddisfacimento dei requisiti di idoneità da parte dell'azienda, compresi la capitalizzazione di mercato minima, il volume medio di scambi giornalieri e la classificazione nell'industria biotecnologica.
L'NBI monitora le performance dei titoli biotecnologici e farmaceutici quotati su Nasdaq seguendo una metodologia modificata ponderata per la capitalizzazione. Il CEO Neil F. McFarlane ha sottolineato che questo sarà un anno trasformativo per Zevra, notando che l'inclusione nell'indice aumenterà il profilo dell'azienda tra i fondi biotecnologici e i gestori di portafoglio.
Zevra Therapeutics (ZVRA) anunció su próxima inclusión en el Índice de Biotecnología Nasdaq (NBI) a partir del 23 de diciembre de 2024, como parte de la reconstitución anual del índice. La inclusión refleja que la compañía ha cumplido con los requisitos de elegibilidad, que incluyen la capitalización mínima del mercado, el volumen promedio de transacciones diarias y la clasificación en la industria biotecnológica.
El NBI rastrea el rendimiento de los valores biotecnológicos y farmacéuticos listados en Nasdaq bajo una metodología de ponderación por capitalización modificada. El CEO Neil F. McFarlane destacó que este será un año transformador para Zevra, señalando que la inclusión en el índice elevará el perfil de la empresa entre los fondos de biotecnología y los administradores de cartera.
제브라 테러퓨틱스 (ZVRA)는 나스닥 생명공학 지수 (NBI)에 2024년 12월 23일부터 포함된다고 발표했습니다. 이는 연례 지수 재조정의 일환으로 이루어집니다. 이 포함은 최소 시장 자본금, 평균 일일 거래량, 생명공학 산업 분류를 포함한 적격 요건을 충족한 회사의 결과를 반영합니다.
NBI는 수정된 자본금 가중 방법론에 따라 나스닥에 상장된 생명공학 및 제약 증권의 성과를 추적합니다. CEO 닐 F. 맥팔레인은 올해가 제브라에 있어 변혁의 해가 될 것이라고 강조하며, 지수 포함이 생명공학 펀드 및 포트폴리오 매니저들 사이에서 회사의 프로필을 상승시킬 것이라고 언급했습니다.
Zevra Therapeutics (ZVRA) a annoncé son inclusion prochaine dans l'Indice Biotechnologique Nasdaq (NBI), à compter du 23 décembre 2024, dans le cadre de la réconstitution annuelle de l'indice. L'inclusion reflète que l'entreprise a satisfait aux exigences d'éligibilité, y compris une capitalisation boursière minimale, un volume moyen de transactions quotidien et une classification dans l'industrie biotechnologique.
L'NBI suit la performance des valeurs boursières biotechnologiques et pharmaceutiques cotées sur Nasdaq selon une méthodologie modifiée pondérée par la capitalisation. Le PDG Neil F. McFarlane a souligné que cette année sera transformante pour Zevra, notant que l'inclusion dans l'indice augmentera le profil de l'entreprise parmi les fonds biotechnologiques et les gestionnaires de portefeuille.
Zevra Therapeutics (ZVRA) gab bekannt, dass das Unternehmen ab dem 23. Dezember 2024 in den Nasdaq Biotechnology Index (NBI) aufgenommen wird, im Rahmen der jährlichen Neustrukturierung des Index. Die Aufnahme spiegelt wider, dass das Unternehmen die Berechtigungskriterien erfüllt hat, einschließlich einer minimalen Marktkapitalisierung, einem durchschnittlichen täglichen Handelsvolumen und einer Klassifizierung in der Biotechnologiebranche.
Der NBI verfolgt die Performance von Biotechnologie- und Pharmakurswerten, die an Nasdaq gelistet sind, unter einer modifizierten marktkapitalisierungsgewichteten Methodik. CEO Neil F. McFarlane betonte, dass dies ein transformatives Jahr für Zevra sein wird und bemerkte, dass die Aufnahme in den Index das Profil des Unternehmens bei Biotech-Fonds und Portfoliomanagern erhöhen wird.
- Addition to Nasdaq Biotechnology Index, increasing visibility to institutional investors
- Meets minimum market cap and trading volume requirements for index inclusion
- None.
CELEBRATION, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced its upcoming addition to the Nasdaq Biotechnology Index (Nasdaq: NBI) (“NBI”) as part of the annual reconstitution of the 2024 Nasdaq indexes. Zevra’s inclusion in the NBI will be effective after the U.S. market opens on Monday, December 23, 2024.
“The past year has been transformational for Zevra as we continue to drive awareness among the investment community and we are proud to be added to the Nasdaq Biotechnology Index, which further raises our profile given the importance of the index to biotech funds and portfolio managers,” said Neil F. McFarlane, Zevra’s President and Chief Executive Officer.
The Nasdaq Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The Nasdaq Biotechnology Index is calculated under a modified capitalization-weighted methodology. Companies in the Nasdaq Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume and an ICB industry code of “Biotechnology,” among other criteria. Nasdaq selects constituents once annually in December.
For more information about the Nasdaq Biotechnology Index, please visit https://indexes.nasdaqomx.com/Index/Overview/NBI.
About Zevra:
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community.
For more information, please visit www.zevra.com or follow us on X (formerly Twitter) and LinkedIn.
Caution Concerning Forward-Looking Statements:
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding upcoming events or Zevra’s participation at such events. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2023, Zevra’s Quarterly Report for the quarter ended September 30, 2024, and Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Zevra Contact
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
Russo Partners Contact
David Schull
+1 (858) 717-2310
david.schull@russopartnersllc.com
FAQ
When will Zevra Therapeutics (ZVRA) be added to the Nasdaq Biotechnology Index?
What are the requirements for ZVRA to join the Nasdaq Biotechnology Index?
How will ZVRA's addition to the Nasdaq Biotechnology Index benefit investors?
What type of weighting methodology does the Nasdaq Biotechnology Index use for ZVRA?
